ANIP ANI Pharmaceuticals, Inc.

69.13USD-3.27%Mkt Cap: 1.57B USDP/E: 14.02

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel …

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap1.57B USD
Enterprise Value1.69B USD
Revenue (TTM)1.04B USD
Gross Profit542.06M USD
Net Income (TTM)78.34M USD
Revenue/Share49.60 USD
Last Price69.13 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees970
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)14.02
P/E (Forward)6.78
PEG1.76
EV/EBITDA7.20
EV/Revenue1.63
P/S1.51
P/B2.32
EPS (TTM)5.03 USD
EPS (Forward)10.20 USD
52W Range
67.147% of range95.45
52W High95.45 USD
52W Low67.14 USD
Profitability
Gross Margin61.36%
Oper. Margin14.66%
EBITDA Margin22.60%
Profit Margin8.87%
ROE14.49%
ROA5.44%
ROIC7.70%
ROCE6.99%
Growth
Revenue Growth27.60%
Earnings Growth33.40%
Cash Flow & Leverage
Operating CF185.22M USD
CapEx (TTM)34.32M USD
FCF Margin17.67%
FCF Yield11.71%
Net Debt180.39M USD
Net Debt/EBITDA0.77
Net Debt/FCF0.98
Balance Sheet
Debt/Equity1.14
Current Ratio2.75
Quick Ratio2.25
Book Value/Sh29.84 USD
Cash/Share20.63 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJul 18, 2013
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)103.38 USD
Upside (mean)+49.5%
Target Range85.00 USD – 121.00 USD
85.00+49.5% to mean121.00
# Analysts8
Ownership
Shares Out.22.72M
Float19.42M
Insiders5.42%
Institutions108.56%
Short Interest
Short Ratio10.9d
Short % Float19.25%
Short % Out.15.77%
Shares Short3.58M
Short (prev mo.)3.49M
Technical
SMA 5072.31 (-4.4%)
SMA 20076.95 (-10.2%)
Beta0.47
S&P 52W Chg12.08%
Avg Vol (30d)418.11K
Avg Vol (10d)622.56K
Technical Indicators
RSI (14)42.9
MACD-0.5999
MACD Signal-0.6264
MACD Hist.+0.0265
BB Upper73.98 USD
BB Middle70.95 USD
BB Lower67.92 USD
BB Width8.54%
ATR (14)2.312 USD
Vol Ratio (20d)0.56x

About ANI Pharmaceuticals (NASDAQ: ANIP)

›

ANI Pharmaceuticals (NASDAQ: ANIP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 970 employees.

The shares were at 69.13 USD on 19 November 2026, down 23.4% over 52 weeks. Its 52-week range is 67.14 USD to 95.45 USD: the price is 27.6% below the high and 3.0% above the low.

At a market capitalisation of 1.57B USD, it trades at 14.0 times trailing earnings and 6.8 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 43% for ANIP.

ANI Pharmaceuticals reports return on equity of 14.5%, an operating margin of 14.7% and revenue up 27.6% year over year.

Its debt exceeds its cash by 180.39M USD, a debt-to-equity ratio of 1.14. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 103.38 USD is 49.5% above the current price. The next earnings report is expected on 26 February 2027.